Study findings updated . AI-assisted evidence summary, not individual medical advice or a clinician endorsement.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY1 in 22 infected adults4.5% of infected adults met ME/CFS criteria, vs 0.6% of uninfected adults
About 1 in 22 infected adults met ME/CFS criteria months later.
In the US RECOVER study, 4.5% of adults infected with COVID met ME/CFS criteria months later, versus 0.6% of adults never infected. Compared with matched uninfected people, infection was linked to a hazard ratio of 4.93, about 4.9 times the rate of new ME/CFS. Post-exertional malaise, a crash after even small effort, was the most common symptom, reported by 24.0% of infected people.
With so many Americans infected, even a few percent adds up to a large number of people facing a long, disabling illness, and the crash after effort is the clue to watch for. Observational study using self-reported symptoms that can wax and wane; hospitalized patients were excluded, the 4.93 figure is a hazard ratio, and it cannot prove COVID caused each case.
See the evidence
A US cohort of about 11,800 infected and 1,440 uninfected adults at 83 sites, surveyed every 3 months between 2021 and 2024.
From the study: “The proportion of all RECOVER-Adult participants that met criteria for ME/CFS following SARS-CoV-2 infection was 4.5% (531 of 11,785) compared to 0.6% (9 of 1439) in uninfected participants.”
1 in 22 infected adults
Vernon SD et al. Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult Study. Journal of general internal medicine. 2025.
From the study: “a hazard ratio of 4.93 (95% CI 3.62-6.71)”
1 in 22 infected adults
Vernon SD et al. Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult Study. Journal of general internal medicine. 2025.
From the study: “Post-exertional malaise was the most common ME/CFS symptom in infected participants (24.0%, 2830 of 11,785).”
1 in 22 infected adults
Vernon SD et al. Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult Study. Journal of general internal medicine. 2025.
About half of people with long COVID meet ME/CFS criteria.
1 in 2 with long COVID51% of long COVID patients met ME/CFS criteria, pooled across 13 studies
Pooling 13 studies covering 1,973 people with long COVID, researchers found that 51% met formal diagnostic criteria for ME/CFS. Fatigue, poor sleep and muscle or joint pain were the most common symptoms, and patients also had post-exertional malaise, the crash after effort that is the hallmark of ME/CFS.
For many people with long COVID, the crushing fatigue and crashes after effort fit a known illness, ME/CFS, which gives patients and doctors an existing framework for diagnosis and research. Pooled from studies published 2020 to May 2023 of people already diagnosed with long COVID, so it does not show how often COVID itself leads to ME/CFS.
See the evidence
A systematic review and meta-analysis of 13 studies, about 2,000 long COVID patients in total, published between 2020 and May 2023.
From the study: “Our meta-analysis indicated that 51% (95% CI, 42%-60%) of LC patients satisfied ME/CFS diagnostic criteria, with fatigue, sleep disruption, and muscle/joint pain being the most common symptoms.”
1 in 2 with long COVID
Dehlia A et al. The persistence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) after SARS-CoV-2 infection: A systematic review and meta-analysis. The Journal of infection. 2024.
From the study: “We identified 13 eligible studies that reported a total of 1973 LC patients.”
1 in 2 with long COVID
Dehlia A et al. The persistence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) after SARS-CoV-2 infection: A systematic review and meta-analysis. The Journal of infection. 2024.
From the study: “Importantly, LC patients also experienced the ME/CFS hallmark symptom, post-exertional malaise.”
1 in 2 with long COVID
Dehlia A et al. The persistence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) after SARS-CoV-2 infection: A systematic review and meta-analysis. The Journal of infection. 2024.
Muscle abnormalities worsened after exercise-triggered crashes in long COVID.
All 25 patients crashedEvery long COVID patient had a crash a day after one maximal cycling test
25 long COVID patients with post-exertional malaise and 21 people who had fully recovered from mild COVID did one all-out cycling test, with thigh muscle samples taken before and a day after. Every patient crashed. Their muscles already produced energy less well, and muscle damage and deposits of clumped protein called amyloid worsened after the crash.
The crash after effort shows up as measurable changes in muscle, not just tiredness or low motivation, which helps explain why pushing through can leave people with long COVID worse off. Small study of 25 patients aged 18 to 65 without major other illnesses; it tracked changes after a single test and cannot show long-term effects of exercise.
See the evidence
A case-control study comparing 25 long COVID patients with 21 matched people who had recovered from mild COVID, using exercise tests and muscle biopsies before and after a crash.
From the study: “All long COVID patients experienced post-exertional malaise following maximal exercise, despite considerable heterogeneity in exercise capacity.”
All 25 patients crashed
Appelman B et al. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nature communications. 2024.
From the study: “Oxidative phosphorylation (OXPHOS) capacity was significantly lower in patients with long COVID ( n = 25) compared to healthy controls ( n = 21)”
All 25 patients crashed
Appelman B et al. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nature communications. 2024.
From the study: “severe exercise-induced myopathy and tissue infiltration of amyloid-containing deposits in skeletal muscles of patients with long COVID worsen after induction of post-exertional malaise”
All 25 patients crashed
Appelman B et al. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nature communications. 2024.
People with long COVID reported fewer crashes during six weeks of pacing.
1.1 crashes a weekAverage crash episodes in week 6 of a pacing plan, down from 3.4 in week 1
31 people with long COVID followed a pacing plan, rating how hard activities felt and keeping effort within set limits while stepping up slowly. Crashes, called post-exertional symptom exacerbation, fell from 3.4 in week 1 to 1.1 in week 6 as activity rose modestly. Their self-rated health score rose from 51.4 to 60.6 points.
It suggests that keeping effort within limits may reduce crashes while still letting activity build slowly, but only a trial with a comparison group can show the plan itself made the difference. No comparison group and only 31 people at one Leeds rehabilitation service, so natural improvement over time could explain some of the change.
See the evidence
A 6-week prospective study of 31 adults with long COVID, median 17 months of symptoms, in a Leeds, UK, community rehabilitation service.
From the study: “Patients who followed the WHO Borg pacing protocol for 6 weeks reported a reduction in the number of PESE episodes experienced, from a mean of 3.4 episodes in Week 1 down to 1.1 in Week 6.”
1.1 crashes a week
Parker M et al. Effect of using a structured pacing protocol on post-exertional symptom exacerbation and health status in a longitudinal cohort with the post-COVID-19 syndrome. Journal of medical virology. 2023.
From the study: “Mean EQ-5D 5L scores improved from 51.4 to 60.6 points”
1.1 crashes a week
Parker M et al. Effect of using a structured pacing protocol on post-exertional symptom exacerbation and health status in a longitudinal cohort with the post-COVID-19 syndrome. Journal of medical virology. 2023.
From the study: “leaving 31 participants for data analysis”
1.1 crashes a week
Parker M et al. Effect of using a structured pacing protocol on post-exertional symptom exacerbation and health status in a longitudinal cohort with the post-COVID-19 syndrome. Journal of medical virology. 2023.
COVID-triggered ME/CFS stayed severe up to 20 months; other long COVID improved.
20 months, still severePatients meeting ME/CFS criteria after COVID, followed at a Berlin fatigue clinic
At a Berlin clinic, people with disabling fatigue after COVID were followed for up to 20 months. Those meeting ME/CFS criteria stayed severely ill while the rest improved: at the last visit, 46% of the ME/CFS group still had severe fatigue, versus 3% of the others. At the start, 53 of 55 in the ME/CFS group said they could not work even part time.
Meeting ME/CFS criteria after COVID signals a much slower course than other long COVID, so many people may need long-term support at work and home rather than a quick return. Small single-clinic study in Germany of patients referred for severe fatigue; 19 people dropped out, most reporting improvement, which may skew results.
See the evidence
A prospective cohort of 106 adults with moderate to severe fatigue after COVID at Charité in Berlin, Germany, followed from 2020 to 2022.
From the study: “Patients with PCS-ME/CFS reported persistently high severity of most symptoms up to 20 months after infection, while patients with PCS showed overall health improvement.”
20 months, still severe
Legler F et al. Long-term symptom severity and clinical biomarkers in post-COVID-19/chronic fatigue syndrome: results from a prospective observational cohort. EClinicalMedicine. 2023.
From the study: “At follow-up 2, only 3% of PCS but 46% of patients with PCS-ME/CFS still reported CFQ scores ≥ 28 points.”
20 months, still severe
Legler F et al. Long-term symptom severity and clinical biomarkers in post-COVID-19/chronic fatigue syndrome: results from a prospective observational cohort. EClinicalMedicine. 2023.
From the study: “53 of 55 PCS-ME/CFS and 43 of 51 PCS reported that they are unable to work full- or part-time (Bell scale <70/100).”
20 months, still severe
Legler F et al. Long-term symptom severity and clinical biomarkers in post-COVID-19/chronic fatigue syndrome: results from a prospective observational cohort. EClinicalMedicine. 2023.
Full recovery from untreated chronic fatigue syndrome is rare; many improve.
1 in 20 fully recoverMedian full recovery rate across 14 studies of CFS; a median 39.5% improved
Before COVID, a review of 14 follow-up studies of people diagnosed with chronic fatigue syndrome, an older name for ME/CFS, found a median full recovery rate of just 5%. A median 39.5% improved. In the three studies that tracked work, 8% to 30% were back at work at follow-up.
If these older patterns hold for COVID-triggered ME/CFS, many people can hope to improve but few should expect a full return to their old health, which matters for planning work and care. An older review of pre-pandemic studies of patients without systematic treatment; outcomes for ME/CFS triggered by COVID may differ.
See the evidence
A systematic review of follow-up studies of people diagnosed with chronic fatigue syndrome, 14 of which used formal criteria, published before COVID.
From the study: “for the 14 studies of subjects meeting operational criteria for CFS, the median full recovery rate was 5% (range 0-31%)”
1 in 20 fully recover
Cairns R et al. A systematic review describing the prognosis of chronic fatigue syndrome. Occupational medicine (Oxford, England). 2005.
Nearly half of long COVID survey respondents had to cut work hours.
45% cut work hoursShare of long COVID survey respondents on reduced hours; 22.3% more were not working
In an international online survey of people with long COVID, 45.2% were working reduced hours compared with before they fell ill, and another 22.3% were not working because of illness. 85.9% had relapses, mainly triggered by exercise, physical or mental activity, and stress. For more than 91%, recovery took longer than 35 weeks.
Long COVID with crashes after effort can push people out of work for many months, which affects family income, employers and disability systems, not just health. Self-selected online survey recruited through support groups and social media, with illness starting before June 2020; it cannot show how common these problems are among all infected people.
See the evidence
An online survey of about 3,800 people with confirmed or suspected COVID from 56 countries, collected September to November 2020 via support groups.
From the study: “1700 respondents (45.2%) required a reduced work schedule compared to pre-illness, and an additional 839 (22.3%) were not working at the time of survey due to illness.”
45% cut work hours
Davis HE et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021.
From the study: “85.9% of participants (95% CI, 84.8% to 87.0%) experienced relapses, primarily triggered by exercise, physical or mental activity, and stress.”
45% cut work hours
Davis HE et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021.
Low-dose naltrexone looks promising for long COVID but lacks randomized trials.
Only 155 patients so farAll from small before-and-after studies; no randomized trials found yet
Low-dose naltrexone (LDN) is used off-label for long COVID and ME/CFS. This review found no randomized trials, only four small before-and-after studies with 155 patients in the USA and Ireland. Patients reported less fatigue, pain and brain fog and better sleep, but the authors rate the certainty of evidence as low. Placebo-controlled trials are under way.
Improvement seen without a comparison group can reflect natural recovery or expectation, so the true benefit of LDN for long COVID will remain unknown until placebo-controlled results arrive. All included studies were small, uncontrolled before-and-after designs, and the authors rate the certainty of evidence as low.
See the evidence
A systematic review and meta-analysis, searched through May 2026, pooling four small observational studies with 155 patients from the US and Ireland.
From the study: “Of 397 titles and abstracts screened, no randomised controlled trials were identified.”
Only 155 patients so far
Byambasuren O et al. Effect of low-dose naltrexone for long COVID: a systematic review and meta-analysis. BMJ open. 2026.
ME/CFS and Long COVID showed different immune-cell activation patterns
An exploratory cross-sectional study found different monocyte and dendritic-cell activation patterns in ME/CFS and Long COVID groups.
The comparison included 103 ME/CFS participants, 63 Long COVID participants and 41 healthy controls. Group immune profiles are not a validated diagnostic test or proof of different causal mechanisms.
Study details & original results
Petrov, Steliyan et al.. Comprehensive Immunophenotyping of Monocytes and Dendritic Cells Suggests Distinct Pathophysiology in Chronic Fatigue Syndrome and Long COVID.. International Journal of Molecular Sciences. 2026.
Exploratory cross-sectional immune-cell comparison of 103 ME/CFS participants, 63 Long COVID participants and 41 healthy controls; group profiles are not a validated diagnostic test.
Different monocyte and dendritic-cell activation patterns in ME/CFS and Long COVID
Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.
WHEN YOU WANT TO GO DEEPERSee all 1 findingsOriginal results, comparisons and study details.
1 of 1 source groupsFindings stay together with their study.
SOURCE 011 finding
Petrov, Steliyan et al.. Comprehensive Immunophenotyping of Monocytes and Dendritic Cells Suggests Distinct Pathophysiology in Chronic Fatigue Syndrome and Long COVID.. International Journal of Molecular Sciences. 2026.
Exploratory cross-sectional immune-cell comparison of 103 ME/CFS participants, 63 Long COVID participants and 41 healthy controls; group profiles are not a validated diagnostic test.
Added
Different monocyte and dendritic-cell activation patterns in ME/CFS and Long COVIDSource [1]
Browse the 9 original sourcesThe complete bibliography behind this monitor.
[1]
Petrov, Steliyan et al.. Comprehensive Immunophenotyping of Monocytes and Dendritic Cells Suggests Distinct Pathophysiology in Chronic Fatigue Syndrome and Long COVID.. International Journal of Molecular Sciences. 2026.
Vernon SD et al. Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult Study. Journal of general internal medicine. 2025.
Dehlia A et al. The persistence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) after SARS-CoV-2 infection: A systematic review and meta-analysis. The Journal of infection. 2024.
Parker M et al. Effect of using a structured pacing protocol on post-exertional symptom exacerbation and health status in a longitudinal cohort with the post-COVID-19 syndrome. Journal of medical virology. 2023.
Legler F et al. Long-term symptom severity and clinical biomarkers in post-COVID-19/chronic fatigue syndrome: results from a prospective observational cohort. EClinicalMedicine. 2023.
Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results. Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed.
Download the findings and bibliography displayed in this page snapshot. Values and confidence intervals remain as reported text; this is not a pooled estimate or a systematic review. Product-label observations and editorial takeaways are excluded.
These findings may omit evidence or contain errors and have not been reviewed by a clinician. A citation or download does not establish source verification. Read the original studies for their methods and limitations.
The October 2026 COVID citation audit found errors in this collection. These downloads may still contain affected findings and bibliography entries. Read the correction record before using them.
“Added” dates record entry into the monitor, not publication or clinical review. A null original acquisition or derivation means its historical record is unknown; a current record or verification has its own observation time. The SHA-256 snapshot identifier binds the downloadable public fields. CSV includes finding rows and bibliography-only source rows; JSON includes both lists. Spreadsheet-sensitive CSV cells begin with an apostrophe for safety; JSON preserves the original text.
For attribution, cite ModernDoc and the page URL, data update date and snapshot identifier in the download. Original studies retain their own rights; this download does not grant a licence to their full text.